- Home
- CRH vs MRNA Comparison
CRH vs MRNA Comparison
Compare CRH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRH | MRNA |
|---|---|---|
| Founded | 1936 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 61.6B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRH | MRNA |
|---|---|---|
| Price | $90.10 | $221.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 23 | 23 |
| Target Price | $122.72 | ★ $138.37 |
| AVG Volume (30 Days) | 4.4M | ★ 16.9M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | 9.76 | ★ 21.77 |
| EPS | ★ 3.79 | N/A |
| Revenue | ★ $37,447,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $5.33 | $8.13 |
| Revenue Next Year | $6.53 | $16.26 |
| P/E Ratio | $23.96 | ★ N/A |
| Revenue Growth | ★ 5.27 | 4.29 |
| 52 Week Low | $78.62 | $22.28 |
| 52 Week High | $131.55 | $254.48 |
Technical Indicators
Market Signals| Indicator | CRH | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 56.30 |
| Support Level | $79.38 | $45.39 |
| Resistance Level | $103.28 | $254.48 |
| Average True Range (ATR) | 2.40 | 22.75 |
| MACD | 1.10 | -3.28 |
| Stochastic Oscillator | 87.67 | 53.57 |
Price Performance
Historical ComparisonAbout CRH CRH PLC
CRH is a global manufacturer of a range of building products used in construction projects, operating via a vertically integrated business model. The past decade has seen CRH transform into a leading building materials business, with increasing exposure to upstream building activities such as aggregates and cement. CRH's geographic footprint is mostly across developed markets. North America is CRH's largest market and accounts for 75% of EBITDA. The company is the largest producer of aggregates and asphalt in the US.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.